Accessibility Menu
AccuStem Sciences logo

AccuStem Sciences(OTC) ACUT

Market Cap$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-92%
5 YearN/A
1 Year-92%
1 Month-16%
$0.16
-28.89%
-0.07Today
AccuStem Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.162026-08-28
AccuStem Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.162026-08-21
1 month-15.79%USD 0.192026-07-29
3 month-37.86%USD 0.262026-05-29
Year to date-80.33%USD 0.812025-12-31
1 year-91.92%USD 1.982025-08-28
3 year-82.22%USD 0.902023-08-29
Since inception-92%USD 2.002022-03-02

AccuStem Sciences Financials at a Glance

Market Cap

$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$98.40K

Net Income (TTM)

-$1.65M

EPS (TTM)

-$0.10

P/E Ratio

-1.56

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.16

Volume

85

Open

$0.23

Previous Close

$0.16

Daily Range

$0.16 - $0.23

52-Week Range

$0.15 - $2.25

Estimated Earnings Date

Aug 14, 2026

ACUT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About AccuStem Sciences

Accustem helps doctors predict cancer risks using gene-based tests. Its tools guide treatment choices for breast and lung cancer patients. These tests aim to reduce unnecessary procedures and improve patient care.

Gene Test Lineup: What’s in the Toolbox?

  • MicroRNA Signature Classifier (MSC): Identifies if lung nodules are cancerous or benign; for patients with suspicious lung scans. (0% of revenue, pre-commercial)
  • StemPrintER: Predicts risk of breast cancer returning in certain patients; helps guide follow-up care. (0% of revenue, pre-commercial)
  • Spare: Combines StemPrintER with two clinical markers for more detailed breast cancer risk assessment. (0% of revenue, pre-commercial)
  • Ancillary Laboratory Tests: Includes gene panels and other lab tests to support main products; targets oncology clinics. (0% of revenue, pre-commercial)

Growth Moves: The Expansion Playbook

  • Signed a license deal with IEO/University of Milan for StemPrintER; milestone payments tied to progress.
  • Partnered with EmeritusDx in 2025 to process tests in a US lab, with plans to obtain CLIA certification.
  • Plans to launch the MSC lung test in early 2026, expanding into lung cancer diagnostics.
  • Developing additional lab tests to complement core offerings and increase revenue potential.

Why Accustem Catches the Eye

Accustem focuses on personalized cancer diagnostics using gene-based technology. Its strategy relies on clinical validation and partnerships for lab processing. The company aims to expand its test platform to more cancer types.

Five Things You Need to Know

  • No revenue reported for Q2 2025 or prior periods; all products are pre-commercial.
  • Net loss was $401,403 in Q2 2025, up 44% from Q2 2024.
  • Cash used in operations was $269,029 for Q2 2025, a 28.6% increase year-over-year.
  • Cash balance was $31,341 as of June 30, 2025; working capital deficit was $2.53 million.
  • Company relies on related party funding and needs new financing to continue operations past August 2025.

Bottom Line

Accustem is a small, early-stage company developing gene-based cancer tests. Its future depends on successful product launches and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Wendy Blosser

Website

accustem.com

Headquarters

New York City, NY 10001, US

ACUT Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1780.03%

Net Income Margin

-1680.03%

Return on Equity

46.23%

Return on Capital

N/A

Return on Assets

-102.92%

Earnings Yield

-64.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

16.07M

Volume

85

Avg. Volume

3.52K

Financials (TTM)

Gross Profit

$98.40K

Operating Income

-$1.75M

EBITDA

-$1.23M

Operating Cash Flow

-$1.20M

Capital Expenditure

-$1.00

Free Cash Flow

-$1.20M

Cash & ST Invst.

$12.93K

Total Debt

$62.64K

AccuStem Sciences Performance Analysis

AccuStem Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
AccuStem Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
AccuStem Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.34474.5%
20232023-12-31USD -0.18-46.9%
20242024-12-31USD -0.13-27.2%
20252025-12-31USD -0.12-12.4%
AccuStem Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.4%
Q42025-12-31-42.6%
Q12026-03-3114.9%
Q22026-06-3048.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$98.40K

N/A

Gross Profit

$98.40K

+93814.3%

Gross Margin

100.00%

N/A

Market Cap

$2.57MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$642.90K

N/A

Employees

4

N/A

Net Income

-$252.57K

+37.1%

EBITDA

-$252.57K

+37.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$12.93K

-58.8%

Total Debt

$62.64K

-5.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$62.64K

-5.7%

Return on Assets

-1.03%

N/A

Return on Invested Capital

42.54%

N/A

Free Cash Flow

-$248.85K

+7.5%

Operating Cash Flow

-$248.85K

-1253.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PPCBPropanc Biopharma, Inc.
$1.35+0.00%
HSITFHadasit Bio-Holdings Ltd
$0.12+0.00%
SYGGFSynairgen plc
$0.00+0.00%
ZHCLFZenith Capital Corp.
$0.05+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About ACUT

What is the current price of AccuStem Sciences?

AccuStem Sciences is trading at $0.16 per share.

What is the 52-week range for AccuStem Sciences?

Over the past 52 weeks, AccuStem Sciences has traded between $0.15 and $2.25.

How much debt does AccuStem Sciences have?

As of the most recent reporting period, AccuStem Sciences reported total debt of $62.64K.

How much cash does AccuStem Sciences have on hand?

AccuStem Sciences reported $12.93K in cash and cash equivalents in its most recent financial results.

What is AccuStem Sciences’s dividend yield?

AccuStem Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services